Investor presentation
Logotype for BioHarvest Sciences Inc

BioHarvest Sciences (BHST) Investor presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for BioHarvest Sciences Inc

Investor presentation summary

22 Oct, 2026

Business model and guidance

  • 2026 revenue guidance: $37–40M total, including $33–35M D2C and $4–5M CDMO, excluding internal VINIA transfers.

  • D2C is led by VINIA, with subscription sales and planned expansion into hydration, chews and hot beverages; the strategy is to move the business toward profitability and disciplined cash generation.

  • The platform combines D2C products with CDMO development, manufacturing and potential royalty economics across four industries.

  • 2025 revenue was reported at $35M, with $100M in cumulative sales; the presentation also cites 15 patents.

Plant cell platform and infrastructure

  • Proprietary plant-cell culture uses a cell line derived from one plant, then propagates it in industrial bioreactors to produce plant-derived molecules at scale.

  • Claimed platform benefits include controlled consistency and purity, non-GMO production, lower COGS versus extraction, and enhanced potency through elicitation methods.

  • Current annual production capacity is 20–25 tons, with a stated expansion path to 75+ tons; historical facility capex was $5M.

  • AI-supported computer vision, sensor data fusion and predictive models are intended to improve yield, consistency, discovery and scale-up throughput.

Commercial and development pipeline

  • Four third-party programs are advancing across cosmetics and fragrances, nutraceuticals, pharma and biotech, and nutrition and sweeteners.

  • A 20-ton manufacturing and supply agreement for a rare botanical luxury fragrance is expected to generate $20–30M revenue in 2027–2028.

  • The fragrance program completed Stage 1 and entered Stage 2; a manufacturing and supply agreement was signed in Q3 2026.

  • The Saffron Tech program completed Stage 1 in Q2 2026; the Tate & Lyle program added a second sweetener molecule after the platform demonstrated production capability for the targeted molecule in Q4 2026.

  • CDMO economics progress from paid development stages to commercial manufacturing revenue and potential royalties or ownership participation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from BioHarvest Sciences